3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
8
Unknown
2
Terminated
2
Recruiting
2
Suspended
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Conditions
Breast Neoplasms
35
Lymphoma, Large B-Cell, Diffuse
22
Sarcoma
19
Lymphoma
19
Carcinoma, Hepatocellular
12
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Lymphoma, Non-Hodgkin
9
Hodgkin Disease
9
Multiple Myeloma
8
Leukemia
8
Neuroblastoma
6
Liver Neoplasms
6
Lymphoma, Follicular
5
Immunoblastic Lymphadenopathy
5
Ovarian Neoplasms
4
Lymphoma, T-Cell, Peripheral
4
Lymphoma, Mantle-Cell
4
Triple Negative Breast Neoplasms
3
Recurrence
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Osteosarcoma
3
Neoplasms, Plasma Cell
3
Lymphoma, Large-Cell, Immunoblastic
3
Lymphoma, Large-Cell, Anaplastic
3
Liposarcoma
3
Leiomyosarcoma
3
Chondrosarcoma
3
Burkitt Lymphoma
3
Wilms Tumor
2
Rhabdomyosarcoma
2
Interventions
Cyclophosphamide
5
fludarabine
4
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
3
Gemcitabine
3
fludarabine phosphate
2
endostar protein
2
Melphalan
2
Etoposide
2
Doxorubicin
2
Cisplatin
2
Alemtuzumab
2
thymoglobulin
1
spartalizumab
1
selinexor
1
pembrolizumab
1
Vindesine
1
Vincristine
1
Sensitivity and Specificity
1
Rituximab
1
Prednisone
1
Prednisolone
1
Methylprednisolone
1
Interleukin-2
1
Flavin-Adenine Dinucleotide
1
Epirubicin
1
Endostatins
1
Drug Therapy
1
Dexamethasone
1
Cytarabine
1
Clinical Protocols
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Unknown
×
Lymphoma, T-Cell
×
Doxorubicin
×
Clear all
NCT01719835
2018-03-15
CHEMO-T
Royal Marsden NHS Foundation Trust
Phase 2
Unknown
87 enrolled
NCT00725231
2012-05-07
A-CHOP-14
University of Göttingen
Phase 3
Unknown
274 enrolled